СТРИПЕР Роберт Т.;ИЗБИЦКА Эльзбета;СТРИПЕР Роберт Т.
发明人:
СТРИПЕР Роберт Т.,ИЗБИЦКА Эльзбета
申请号：
RU2014146291
公开号：
RU2014146291A
申请日:
2013.04.15
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of modulating markers in tissue, comprising introducing into the tissue a composition containing a mixture of azelaic acid esters (AAE), where the markers include markers associated with activation of protein kinase C, which is induced by exposure to tissues with croton oil. The method of claim 1, wherein the mixture comprises dimethiazelate and diethylazelate. A method for modulating markers in tissue, comprising introducing into the tissue a composition comprising a mixture of azelaic esters (AAE), where the markers include inflammatory markers. The method of claim 3, wherein the mixture comprises dimethiazelate and diethylazelate. The method of claim 3, wherein the markers include interleukins. The method of claim 5, wherein the interleukins include IL-4 and IL-10.7. The method of claim 6, wherein the levels of IL-4 and IL-10 released from the tissues are increased. The method of claim 6, wherein the levels of IL-4 and IL-10 in the tissues are reduced. The method of claim 5, wherein the interleukins include IL-17 and IL-23.10. The method of claim 9, wherein the levels of IL-17 and IL-23 released from the tissues are suppressed. The method of claim 9, wherein the levels of IL-17 and IL-23 in the tissues increase. The method of claim 1, wherein the method is carried out in vitro. The method of claim 1, wherein the method is carried out in vivo. A method for treating a subject having a disease associated with activation of protein kinase C or inflammatory markers, comprising administering to the subject a composition comprising a mixture of azelaic acid esters. The method of claim 14, wherein the mixture comprises dimethylazelate and diethylazelate. The method according to p. 14, in which the mixture is present in the range from about 1% of the mass. up to about 10% of the mass. from the composition. 17. The method of claim 14, wherein the composition is a topical preparation. The method of claim 17, wherein the composition further comprises a carrier, a
